索菲布韦联合利巴韦林与干扰素治疗1b型丙肝的临床效果观察

Sofosbuvir combined with Ribavirin and Interferon in treatment of type 1b hepatitis C

目的:观察索菲布韦联合利巴韦林与干扰素治疗1b型丙肝的临床效果。方法:选取90例1b型丙肝患者作为观察对象,按随机数字表法将其分为观察组与对照组各45例。对照组给予利巴韦林+干扰素治疗,观察组在对照组基础上给予索菲布韦治疗。比较两组病毒应答情况、肝功能指标(AST、ALT、ALB、TBIL)水平及不良反应发生情况。结果:观察组治疗2周、6周、12周后的病毒应答率分别为80.00%、100%、100%,均明显高于对照组的48.89%、84.44%、91.11%,差异均有统计学意义(P<0.05)。治疗12周后,观察组AST、ALT、ALB、TBIL水平均明显优于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:索菲布韦联合利巴韦林与干扰素治疗1b型丙肝可有效抑制丙肝病毒复制,改善患者的肝功能,且安全性较高。

Objective:To observe clinical effects of Sofosbuvir combined with Ribavirin and interferon in treatment of type 1b hepatitis C.Methods:A total of 90 patients with type 1b hepatitis C were selected as observation objects.According to the random number table method,they were divided into observation group(n=45)and control group(n=45).The control group was given Ribavirin+interferon,while the observation group was given Sofosbuvir on the basis of the control group.The virus response statuses,liver function index(AST,ALT,ALB,TBIL)levels and incidences of adverse reactions were compared between the two groups.Results:The viral response rates in the observation group 2 weeks,6 weeks and 12 weeks after the treatment were 80.00%,100%,and 100%,separately,which were significantly higher than 48.89%,84.44%,and 91.11%in the control group,and the differences were statistically significant(P<0.05).After 12 weeks'treatment,the levels of AST,ALT,ALB and TBIL in the observation group were significantly better than those in the control group,and the difference was statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Sofosbuvir combined with Ribavirin and interferon can effectively inhibit hepatitis C virus replication and improve liver function in the patients with type 1b hepatitis C with higher safety.